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We have previously shown that prophylactic administration of the liposome-encapsulated immunomodulat-
ing agents muramyl tripeptide phosphatidylethanolamine (MTPPE) and gamma interferon (IFN-g) results in
strongly increased survival of mice from a normally lethal septicemia with Klebsiella pneumoniae. It was
anticipated that the treatment acts on macrophages and nonspecifically augments host resistance to various
infections. In the present study, we provide evidence for a key role for T cells in host defense potentiation by
the liposomal immunomodulators toward K. pneumoniae septicemia. It is shown that both CD4 and CD8 cells
are important in immunomodulation, most likely due to production of IFN-g. Depletion of circulating IFN-g
resulted in strong reduction of the antimicrobial host defense activation. Administration of interleukin-10
resulted in decreased antimicrobial host defense activation by liposomal immunomodulators. Moreover,
administration of liposomal immunomodulators was shown to induce predominantly T-helper type 1 (Th1) cell
populations in the spleen. These findings indicate that immunomodulation with liposomal MTPPE and IFN-g
favors Th1 and NK cell activation.
In several models of infection or tumor therapy, nonspecific
stimulation of the host defense system has been convincingly
shown to be effective. We have previously demonstrated that
prophylactic treatment of mice exhibiting a lethal Klebsiella
pneumoniae septicemia with liposome-encapsulated muramyl
tripeptide phosphatidylethanolamine (LE-MTPPE) or gamma
interferon (LE-IFN-g), or both immunomodulators coencap-
sulated in liposomes (LE-MTPPE/IFN-g), could substantially
augment survival (25). As the liposomes used in these studies
are taken up primarily by cells of the mononuclear phagocyte
system (MPS), it is suggested that these cells are the primary
target for the liposomal immunomodulators (15). Macro-
phages were shown to exhibit intracellular receptors for both
immunomodulators (9, 14, 24), and we demonstrated that
these cells are of major importance in the observed host de-
fense potentiation with LE-MTPPE in vivo (16).
Stimulation of purified macrophages in vitro with LE-MT
PPE, LE-IFN-g, or LE-MTPPE/IFN-g resulted in enhanced
production of oxygen and nitrogen metabolites but not in in-
creased phagocytic activity when K. pneumoniae was added to
the cells (25). These data suggest that activation of MPS cells
is not sufficient to obtain effective killing of this microorgan-
ism. It appeared that these cells lacked important costimulat-
ing signals in vitro. Therefore, it is hypothesized that T cells are
involved in activation of macrophage or MPS as a whole. This
view is supported by studies with mice treated with cyclosporin
A before treatment with liposome-encapsulated immuno-
modulators. Cyclosporin A pretreatment resulted in a dra-
matic reduction of antimicrobial host defense potentiation to-
ward K. pneumoniae infection induced by immunomodulators
(27): the 100% survival rate effected by LE-MTPPE/IFN-g was
reduced to 0%.
In this work, the contribution of T cells and their cytokines
to the efficacy of immunomodulation with LE-MTPPE, LE-
IFN-g, or LE-MTPPE/IFN-g to K. pneumoniae septicemia was
studied in vivo. To this end, mice were depleted of T cells or
T-cell subsets, or the production of specific cytokines (e.g.,
IFN-g and tumor necrosis factor alpha [TNF-a]) was modu-
lated by treatment with neutralizing antibodies. Here we dem-
onstrate, for the first time, an important role for T cells, and in
particular T-helper type 1 (Th1) cells, in nonspecific immuno-
modulation.
MATERIALS AND METHODS
Animals. Specific-pathogen-free female C57BL/Ka mice, 11 to 13 weeks of age
(ITRI-TNO, Rijswijk, The Netherlands), were used.
Bacteria. K. pneumoniae capsular serotype 2 (ATCC 43816) was grown for
16 h at 37°C in Todd-Hewitt broth (Oxoid Ltd., Basingstoke, England). The
bacteria were preserved on ice and washed three times in phosphate-buffered
saline (PBS) directly before use. The 50% lethal dose in C57BL/Ka mice was 2 3
102 bacteria after intraperitoneal (i.p.) injection.
Reagents. LE-MTPPE was kindly provided by Ciba-Geigy (Basel, Switzer-
land). Placebo liposomes (PL) were prepared from a dry lyophilysate composed
of phosphatidylcholine and phosphatidylserine in a molar ratio of 7:3 as previ-
ously described (25). Recombinant murine IFN-g was derived from supernatant
fluid of a CHO cell line that carries and expresses an amplified murine IFN-g
cDNA (8). Murine IFN-g was used at a concentration of 2.5 3 105 U/ml. IFN-g
was purified by affinity chromatography on an anti-rat IFN-g monoclonal anti-
body (MAb DB-1) to a specific activity of 6 3 106 U/mg. Liposomes containing
MTPPE, IFN-g, and MTPPE plus IFN-g were prepared as described previously
(25).
Treatment of mice with immunomodulators. Mice were injected iv with LE-
MTPPE, LE-IFN-g, or LE-MTPPE/IFN-g as previously described (25). Briefly,
mice received a total of five injections, at 48-h intervals, of 25 mg of LE-MTPPE,
* Corresponding author. Present address: Department of Surgical
Oncology, University Hospital Rotterdam/Daniel den Hoed Cancer
Center, P.O. Box 5201, 3008 AE Rotterdam, The Netherlands. Phone:
31 10 408 7682. Fax: 31 10 436 9140. E-mail: tenhagen@heel.fgg.eur.nl.
1962
7,500 U of LE-IFN-g, or 25 mg of MTPPE and 7,500 U IFN-g coencapsulated in
6.25 mg of lipid. Twelve hours after the last dose, mice were infected i.p. with K.
pneumoniae or mock infected with PBS.
Depletion of T cells and T-cell subsets. Mice were depleted of T cells by a
single i.p. injection of 100 mg of 17A2, a mouse CD3-specific rat immunoglobulin
G2b (IgG2b) MAb (17), at 24 h before the first dose with immunomodulator.
Depletion of CD4- or CD8-positive cells was obtained by three i.p. injections of
100 mg of YTS-191 or YTS-169, a CD4- or CD8-specific rat IgG2b MAb,
respectively (5). These antibodies were administered at 72, 48, and 24 h before
the first dose with immunomodulator. Depletion of T cells was evaluated in the
blood and spleen by flow cytometry after staining with anti-CD3 MAb KT3 (28).
Flow cytometry demonstrated a more than 85% depletion of the T-cell fractions
in blood 1 day after injection of the T-cell-specific antibodies. T cells only slowly
returned thereafter. Also in spleen, a pronounced depletion with 17A2 was
obtained, with a maximum of 60% at 5 days after injection. Depletion of CD4-
or CD8-positive cells in spleen was even more pronounced, with maximum levels
of depletion of 85 and 95%, respectively. Controls for injection of IgG2b MAb
were injected with equal amounts of a rat IgG2b anti-b-galactosidase MAb
(PH2-49; a kind gift of W. Van Ewijk, Department of Immunology, Erasmus
University, Rotterdam, The Netherlands).
Depletion of endogenous IFN-g. Endogenous IFN-g was depleted by two i.p.
injections of 100 mg of F3, a mouse IFN-g-specific rat IgG2a MAb (11), at 48 h
before the first dose and 12 h after the last dose with immunomodulator. This
dose and treatment scheme was shown to neutralize all bioactive IFN-g in vivo.
F3 was given as plain ascites fluid (in vitro neutralizing titer of 105 against 30 U
of murine IFN-g per ml; rat Ig content, 3.5 mg/ml). Side effects induced by
injections with IgG2a antibody F3 were evaluated by using a control GL117 rat
IgG2a anti-b-galactosidase MAb (obtained by the courtesy of J. Abrams, DNAX
Research Institute, Palo Alto, Calif.) in control ascites fluid at an equal dose.
Administration of IL-10. Mice were injected i.p. 24 h before the first dose of
immunomodulator with 2 3 106 murine interleukin-10 (IL-10) cDNA-trans-
fected J558 cells encapsulated in alginate as previously described, resulting in
elevated cytokine levels in vivo (23). This cell dose has been widely shown for
several cytokine-transfected cell lines to be effective in vivo. Side effects of
alginate–IL-10 injections were evaluated in mock-transfected J558 cells encap-
sulated in alginate. These cell lines were the kind gift of K. Moore (DNAX
Research Institute).
Depletion of TNF-a. Endogenous TNF-a was depleted by a single i.p. injec-
tion, at 48 h before first dose of immunomodulator, of an optimally titrated dose
of 300 mg of TNF-a-specific rabbit IgG isolated from hyperimmune serum.
Controls were injected with the same amount of rabbit IgG isolated from normal
serum. The rabbit anti-murine TNF-a was obtained by immunizing rabbits with
recombinant murine TNF-a. The capacity to inhibit the biological activity of
recombinant TNF-a was ascertained by assessing its capacity to inhibit the
cytolytic effect of murine TNF-a by purified immune rabbit IgG. The antibodies
did not inhibit the biological activity of murine TNF-b.
Experimental infection with K. pneumoniae. Acquired septicemia was induced
by i.p. inoculation of 103 CFU of K. pneumoniae in mice as described previously
(25). In this model, multiplication of bacteria resulted in delayed but continuous
appearance of bacteria in the blood, eventually leading to septicemia and result-
ing in death. Mice were monitored daily for survival until 28 days after bacterial
inoculation. All mice that died during the experiment were examined for the
presence of K. pneumoniae in liver and blood. Each group contained 20 mice.
Evaluation of major histocompatibility complex class II (Ia) antigen expres-
sion of spleen macrophages by flow cytometry. At 12 h and 4 days after the end
of treatment, spleens were excised, treated with collagenase, and minced into cell
suspensions as described elsewhere (26). Cells were stained with MAb M5/114
(13) directed against Ia antigen, and expression was measured by flow cytometry
on a FACScan (Becton Dickinson, San Jose, Calif.). During analysis, lympho-
cytes were gated out. Expression was calculated as molecules equivalent to
soluble fluorescein isothiocyanate as described by Leenen et al. (13). Three mice
were used per treatment.
Examination of activity of Th1 and Th2 cells in spleen after immunomodula-
tion. T-cell pulse-chase experiments were performed as described previously (3).
Briefly, to examine the effect of immunomodulation on the activity of Th1 and
Th2 cells, spleens were excised from treated mice at 12 h and 4 days after end of
treatment. The spleens were minced into a cell suspension, washed, resuspended
at 200,000 cells per well, and cultured on anti-CD3 MAb-coated 96-well culture
plates. Cells were stimulated with medium or IL-2 (200 U/ml) alone (controls),
with IL-2 (200 U/ml) and IFN-g (400 U/ml) accompanied by anti-IL-4 MAb
11B11 (3) (40 mg/ml) (Th1 pulse), or with IL-2 (200 U/ml) and IL-4 (140 ng/ml)
accompanied by anti-IFN-g MAb XMG1.2 (4) (20 mg/ml) (Th2 pulse). After 4
days of culture at 37°C, cells were washed two times, transferred to 96-well plates
freshly coated with anti-CD3 MAb, and chased with IL-2 (100 U/ml) to induce
production of cytokines. After 4 days of culture at 37°C, supernatants were
harvested and IFN-g and IL-4 levels were measured by sandwich enzyme-linked
immunosorbent assay as described previously (3, 4).
Statistical analysis. Differences in survival curves among groups of mice were
evaluated by log rank test. P values below 0.05 were considered significant.
RESULTS
Effect of depletion of T cells on augmentation of antimicro-
bial host defense by liposomal immunomodulators. It was
shown before that treatment of immunocompetent mice with
LE-MTPPE or LE-IFN-g resulted in a dramatic increase in
host defense; 65% of the mice survived, whereas all control
mice, treated with PL, died within 5 days after inoculation;
treatment with immunomodulators combined by coencapsula-
tion enhanced survival to 100% (25). Control experiments per-
formed during the present study also demonstrated that
LE-MTPPE (n 5 9) or LE-IFN-g (n 5 9) treatment resulted
in 65 or 60% survival, respectively, 21 days after infection (data
not shown). Confirmatory experiments on treatment with LE-
MTPPE/IFN-g performed in this study also demonstrated
100% survival of the mice (Fig. 1). Depletion of T cells with
anti-CD3 MAb 17A2 dramatically reduced the potency of the
immunomodulators (Fig. 1). In LE-MTPPE/IFN-g-treated
mice, survival decreased from 100% in immunocompetent
mice to 15% in T-cell-depleted mice (P , 0.001 compared with
the immunocompetent controls). Survival of LE-MTPPE-
treated mice or LE-IFN-g-treated mice was reduced from 65%
in immunocompetent mice to 15 or 5%, respectively, in T-cell-
depleted mice. Because LE-MTPPE/IFN-g treatment is supe-
rior to treatment with single immunomodulators, the remain-
der of this study focuses on the combination.
Differentiation between contribution of CD4- and CD8-pos-
itive cells in augmentation of antimicrobial host defense by
liposomal immunomodulators. Next we investigated which
subset of T cells is of major importance in the observed reduc-
tion induced by anti-CD3 MAb 17A2 in host defense potenti-
ation after immunomodulation. To this end, mice were de-
pleted of CD4- or CD8-positive cells by using published
dosages and treatment schemes (28). Depletion of CD41 cells
resulted in a dramatic decrease of host defense potentiation by
immunomodulators compared with immunocompetent con-
trols (P , 0.001) (Fig. 2). In mice treated with LE-MTPPE/
IFN-g, survival was reduced from 100 to 15%. Also, depletion
of CD81 cells resulted in a dramatic decrease of host defense
potentiation by immunomodulators (P , 0.001) (Fig. 3). In
mice treated with LE-MTPPE/IFN-g, survival was reduced
from 100% in immunocompetent to 5% in CD8-depleted mice.
Depletion of CD31 T cells as well as depletion of CD4 or CD8
FIG. 1. Survival of T-cell-depleted mice infected by i.p. inoculation of 103
CFU of K. pneumoniae. T cells were depleted by injection of CD3-specific IgG2b
MAb. Mice were treated before infection with LE-MTPPE/IFN-g (—— –),
LE-MTPPE (– – – –), LE-IFN-g (— – –), or PL (———). Control mice were
injected with rat IgG2b anti-b-galactosidase MAb and treated with LE-MTPPE/
IFN-g (— —). Each group contained 20 mice.
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subsets of T cells had no significant influence on survival of
mice treated with PL. In mice treated with LE-MTPPE or
LE-IFN-g depletion of CD41 or CD81 cells also resulted in a
dramatic reduction of survival (P , 0.001 for both [Fig. 2 and
3, respectively]). Taken together, these results indicate that
both CD41 and CD81 T cells are of importance in activation
of the host defense by liposomal immunomodulators.
Effect of depletion of endogenous IFN-g on augmentation of
antimicrobial host defense by liposomal immunomodulators.
Depletion of endogenous IFN-g by treatment with MAb F3
resulted in a diminished host defense augmentation by the
immunomodulators compared with immunocompetent mice
(P , 0.001) (Fig. 4). In LE-MTPPE/IFN-g-treated mice, de-
pletion of endogenous IFN-g resulted in a decline of survival
from 100 to 15%. Mice treated with LE-MTPPE or LE-IFN-g
showed a more rapid decline in survival by IFN-g depletion,
resulting in survival of 15 or 10%, respectively.
Effect of administration of IL-10 on augmentation of anti-
microbial host defense by liposomal immunomodulators. Also
IL-10, produced by i.p.-implanted alginate-encapsulated IL-
10-transfected cells in mice treated with LE-MTPPE/IFN-g,
induced a decreased host defense: survival of 20% in IL-10-
treated mice, compared with 100% in immunocompetent LE-
MTPPE/IFN-g-treated mice (P , 0.001) (Fig. 5). Administra-
tion of IL-10-producing cells in mice treated with LE-IFN-g
resulted in a comparable decreased survival, whereas a more
rapid effect was seen in LE-MTPPE-treated mice.
Effect of depletion of endogenous TNF-a on augmentation
of antimicrobial host defense by liposomal immunomodula-
tors. Administration of TNF-a-specific rabbit IgG to LE-MT-
PPE/IFN-g-treated mice resulted in reduced survival of mice
after infection with K. pneumoniae (P , 0.001), indicating that
stimulation of TNF-a production by macrophages and/or T
cells is also of importance in the described immunomodulation
(Fig. 6).
Effect of immunomodulation on Ia antigen expression of
splenic macrophages. The spleen is an important organ in the
communication between macrophages and T cells, and a large
proportion of the liposomal immunomodulator localizes in the
spleen. Moreover, macrophages are considered to be the tar-
FIG. 2. Survival of CD41 cell-depleted mice infected by i.p. inoculation of
103 CFU of K. pneumoniae. CD41 cells were depleted by injection of CD4-
specific IgG2b MAb. Mice were treated before infection with LE-MTPPE/IFN-g
(—— –), LE-MTPPE (– – – – ), LE-IFN-g (— – –), or PL (——). Control mice
were injected with rat IgG2b anti-b-galactosidase MAb and treated with LE-
MTPPE/IFN-g (— —). Each group contained 20 mice.
FIG. 3. Survival of CD81 cell-depleted mice infected by i.p. inoculation of
103 CFU of K. pneumoniae. CD81 cells were depleted by injection of CD8-
specific IgG2b MAb. Mice were treated before infection with LE-MTPPE/IFN-g
(— –), LE-MTPPE (– – – –), LE-IFN-g (—— – –), or PL (——). Control mice
were injected with rat IgG2a anti-b-galactosidase MAb and treated with LE-
MTPPE/IFN-g (— —). Each group contained 20 mice.
FIG. 4. Survival of mice depleted of endogenous IFN-g and infected by i.p.
inoculation of 103 CFU of K. pneumoniae. IFN-g was depleted by injection of
IFN-g-specific IgG2a MAb. Mice were treated before infection with LE-MT
PPE/IFN-g (—— –), LE-MTPPE (– – – –), LE-IFN-g (—— – –), or PL (——).
Control mice were injected with rat IgG2a anti-b-galactosidase MAb and treated
with LE-MTPPE/IFN-g (— —). Each group contained 20 mice.
FIG. 5. Survival of mice injected i.p. with IL-10-producing cells in alginate
and infected by i.p. inoculation of 103 CFU of K. pneumoniae. Mice were treated
before infection with LE-MTPPE/IFN-g (—— –), LE-MTPPE (– – – –),
LE-IFN-g (—— –), or PL (——). Control mice were injected with mock-trans-
fected alginate-encapsulated cells and treated with LE-MTPPE/IFN-g (— —).
Each group contained 20 mice.
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gets for immunomodulation, and the liposomes used target
mainly these cells. We therefore examined macrophage acti-
vation after immunomodulation in the spleen. Treatment of
mice with LE-MTPPE/IFN-g resulted in enhanced expression
of Ia antigen at 4 days after the end of treatment (Fig. 7). In
addition, complement receptor 3 antigen expression was en-
hanced upon treatment with immunomodulator at 12 h after
the end of treatment (data not shown).
Effect of immunomodulation on Th1 and Th2 cell activity in
the spleen. The T-cell depletion studies indicated an important
role for T cells, in particular cell populations producing IFN-g.
This led us to examine the effect of immunomodulation on Th1
and Th2 cell development in the spleen. The activity of T-cell
subsets was assessed ex vivo as the amount of IFN-g (Th1) and
IL-4 (Th2) produced after immunomodulation. Treatment of
mice with LE-MTPPE/IFN-g resulted in T cells predominantly
producing IFN-g, independently of the culture conditions (Fig.
8). Spleen cells from mice treated with PL produced low levels
of INF-g. However, spleen cells from LE-MTPPE/IFN-g-
treated mice produced high IFN-g levels when cultured in
unsupplemented medium or in medium with IL-2 alone, but
also when stimulated in the Th1 or Th2 direction (P , 0.001),
indicating a strong effect of the immunomodulation on the Th1
population. Whereas T cells from the spleen produced IFN-g
in high amounts under all culture conditions, production of
IL-4 was in most cases below the detection level or even ap-
parently suppressed after immunomodulation. T-cell prolifer-
ation was induced by addition of IFN-g (Th1) or IL-4 (Th2),
which explains the high titers, especially in the Th2 group
represented in Fig. 8D. Taken together, these results indicate
a predominant activation by the liposomal immunomodulators
of NK cells and of CD8 and Th1 cells in the spleen, cells known
to produce IFN-g, and an absence of a significant activation of
Th2 cells, which produce IL-4.
DISCUSSION
We have examined the role of T cells in immunomodulation
by liposomal MTPPE and IFN-g in K. pneumoniae septicemia
in mice. We demonstrate for the first time a key role for T cells
in immunomodulation to gram-negative septicemia. CD4 and
CD8 T cells were shown to be important. Furthermore, IFN-g
was shown to be crucial in enhancement of host defense by
immunomodulators. Therefore, we hypothesize that especially
Th1 cells, CD8-positive cells, and NK cells, all known to pro-
duce IFN-g upon stimulation, are activated in this process by
liposomal immunomodulator-stimulated macrophages. From
experiments with exogenous IL-10, demonstrating that IL-10
can indeed counteract the stimulation of the host defense by
the immunomodulators, it is concluded that Th2 cells do not
play a significant role in the immunomodulation. Th2 cells may
not be stimulated or may be adequately suppressed by IFN-g.
This possibility is supported by our observation that IFN-g
production is increased in the spleen after immunomodulation,
indicating a shift to Th1 cells in the spleen upon treatment with
LE-MTPPE/IFN-g.
In mice, two types of T-helper cells can be distinguished:
Th1, producing IL-2, IFN-g, granulocyte-macrophage colony-
stimulating factor, but little or no IL-4 and IL-5; and Th2,
producing IL-3, IL-4, IL-5, and IL-10 (21). One aspect of the
Th1 response is macrophage activation, which enhances its
capacity to kill intracellular microorganisms. The Th2 re-
sponse, on the other hand, leads to macrophage deactivation
FIG. 6. Survival of mice depleted of endogenous TNF-a and infected by i.p.
inoculation of 103 CFU of K. pneumoniae. TNF-a was depleted by injection of
TNF-a-specific polyclonal rabbit IgG. Mice were treated before infection with
LE-MTPPE/IFN-g (—— –) or PL (——). Control mice were injected with an
equal amount of rabbit IgG and treated with LE-MTPPE/IFN-g (— —). Each
group contained 20 mice.
FIG. 7. Ia antigen expression on spleen cells measured by flow cytometry in mice treated with LE-MTPPE/IFN-g, PL, or PBS. One group of mice was also infected
by i.p. inoculation of 103 CFU of K. pneumoniae (LE-MTPPE/IFN-g day 4 inf) 12 h after the end of treatment. Spleen cells were examined 12 h and 4 days (day 4)
after the end of treatment. Each bar represents the average 1 standard deviation of three mice. FITC, fluorescein isothiocyanate.
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(reviewed in references 19 and 22). The present data indicate
an important role for IFN-g in activation of nonspecific host
defense by liposomal immunomodulators. In immunocompe-
tent mice, NK cells and T cells (Th1 and CD81) produce
IFN-g upon stimulation (29). The presumed cell type respon-
sible for the IFN-g expression in T-cell-deficient mice is there-
fore the NK cell, the only non T cell type reported to produce
IFN-g in vivo (1). However, depletion of T cells, both CD4 and
CD8, was demonstrated to be detrimental for immunomodu-
lation in mice in our septicemia model, which was shown to
depend strongly on IFN-g. In our model, NK cells appeared
not able to substantially induce host defense activation in T-
cell-depleted mice. Taken together, our data show that T cells
are essential for the production of IFN-g to enhance the host
defense upon immunomodulation.
A potent inhibitor of monocyte/macrophage activation is
IL-10, produced by Th2 cells and macrophages. IL-10 inhibits
production of TNF-a, IL-1, and IFN-g by lymphocytes. More-
over, IL-10 is a potent inhibitor of IL-12 production by acti-
vated mononuclear cells (reviewed in references 18 and 20).
IL-12, produced by monocytes/macrophages and B cells, is
required for IFN-g production in synergy with IL-2 (2, 6), and
activation of macrophages by liposomal immunomodulators is
expected to induce release of IL-12, resulting in IFN-g pro-
duction by activated Th1 and CD81 cells. Experiments on the
role of IL-12 in our model are in progress. Others claim that
inhibition of IFN-g production is due primarily to blocking of
the production from accessory cells of IL-12 as well as the
costimulating cytokine IL-1 (7). These results support those of
earlier studies showing that IL-10 does not suppress IFN-g
production by activated lymphocytes directly (10). The present
study shows that exogenous IL-10 has a profound inhibitory
effect on survival of mice treated with liposomal immuno-
modulators, indicating that activation of macrophages most
likely results in activation of Th1 cells and NK cells, probably
through IL-12, resulting in IFN-g production (7, 12).
Macrophages are activated by immunomodulators, as indi-
cated by increased Ia antigen expression on these cells upon
immunomodulation. The immunomodulators are known to in-
duce TNF-a, presumably produced by activated macrophages,
which was shown to be essential for the host defense augmen-
tation by LE-MTPPE/IFN-g. Both macrophages and T cells
appeared to play a role in the augmented resistance to K.
pneumoniae upon immunomodulation. As the placebo-treated
mice all died within 5 days after challenge, the role of specific
antibodies might be limited. However, studies revealed that
injections with LE-MTPPE/IFN-g resulted in a dramatic in-
crease of phagocytic cells, which could explain the augmented
resistance to infections (unpublished data).
Although a dramatic reduction of host defense potentiation
by immunomodulators was noticed after T-cell depletion, in-
dicating a key role function of these cells in this process, sig-
nificant enhancement of the host defense was still seen in most
of the T-cell-depleted groups upon treatment with immuno-
modulators. It appears that in addition to LE-MTPPE/IFN-g,
other, yet unknown T-cell factors must be given to obtain
sufficient host defense activation in T-cell-deficient hosts.
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FIG. 8. Presence of Th1 and Th2 cells in spleens of mice treated with LE-MTPPE/IFN-g, measured by production of IFN-g and IL-4. Three mice were used per
treatment group, and cytokine production was determined in quadruplicate. T cells were isolated 12 h (A and C and 4 days (B and D after the end of treatment. Cells
were cultured in anti-CD3-coated plates in the presence of IL-2 (IL-2), IL-2, IFN-g, and anti-IL-4 (Th1), IL-2, IL-4, and anti-IFN-g (Th2), or medium alone (-).
Horizontal lines represent averages of the determinations. E, PL-treated controls; F, LE-MTPPE/IFN-g-treated mice.
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